公开(公告)号：US20150047634A1

公开(公告)日：2015-02-19

申请号：US14385725

申请日：2013-03-18

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： Kieran Murphy ,  David Mikulis ,  Joseph Barfett

IPC: A61M16/12 ,  A61M16/22 ,  A61M16/10 ,  A61M16/20 ,  A61M16/00 ,  A61M16/06

CPC classification number: A61M16/12 ,  A61M16/0003 ,  A61M16/0045 ,  A61M16/0078 ,  A61M16/06 ,  A61M16/0688 ,  A61M16/1015 ,  A61M16/1075 ,  A61M16/20 ,  A61M16/202 ,  A61M16/208 ,  A61M16/22 ,  A61M35/00 ,  A61M2016/0027 ,  A61M2016/0033 ,  A61M2016/0039 ,  A61M2016/1035 ,  A61M2202/02 ,  A61M2202/0208 ,  A61M2205/3334 ,  A61M2205/3368 ,  A61M2205/8231 ,  A61M2210/0625 ,  Y02E60/324

Abstract: There is provided herein devices for delivering hydrogen to a subject comprising a flow path including a breather bag and an inhalation outlet for engagement with the subject respiratory system; and a breathing gas supply source comprising hydrogen gas and in fluid communication with the flow path. Also provided are devices for the cutaneous delivery of hydrogen.

Abstract translation: 本文提供了用于向受试者输送氢的装置，包括包括通气袋和用于与受试者呼吸系统接合的吸入口的流路; 以及包括氢气并与流动路径流体连通的呼吸气体供应源。 还提供用于皮肤递送氢的装置。

公开(公告)号：US20230384186A1

公开(公告)日：2023-11-30

申请号：US18034278

申请日：2021-10-28

Applicant: UNIVERSITY HEALTH NETWORK

Inventor： Kieran Murphy ,  Diana Vucevic ,  Shafique Keshavjee

IPC: G01N1/30 ,  C12Q1/6806 ,  G01N1/31

CPC classification number: G01N1/30 ,  C12Q1/6806 ,  G01N1/31 ,  G01N2001/302 ,  G01N2001/305

Abstract: Provided is a fixative composition comprising from at least 5 percent to 50 percent syrup, optionally honey, preferably, at least 10 syrup, and dextran and optionally coconut oil, optionally from at least 10 g/L to about 60 g/L of dextran, preferably about 50 g/L and/or from at least 0.5 percent to 15 percent coconut oil, preferably at least 1 percent coconut oil, methods of making the solution, methods of using the solution, for example methods for preserving a biological sample in said solution, and containers and kits comprising the solution.

公开(公告)号：US20160335413A1

公开(公告)日：2016-11-17

申请号：US15154307

申请日：2016-05-13

Applicant: University Health Network

Inventor： Sean Davidson ,  Michael D. Sherar ,  Kieran Murphy ,  Claire McCann ,  Robert Weersink

IPC: G06F19/00 ,  A61B34/00

CPC classification number: G16H50/50 ,  A61B34/00 ,  A61B2018/00577 ,  A61B2034/101

Abstract: Various embodiments are described herein for a system and a method for treatment planning for providing ablative therapy to a patient. The treatment planning may involve segmenting images of the patient to define areas to receive treatment, defining trial parameters, simulating treatment of ablative therapy to the patient according to the trial parameters; analyzing a thermal dose distribution resulting from the simulated treatment to determine treatment effectiveness; determining when the treatment effectiveness meets a treatment effectiveness criteria; and providing an indication of the trial parameters when the treatment effectiveness meets the treatment effectiveness criteria.

Abstract translation: 本文描述了用于为患者提供消融治疗的治疗计划的系统和方法。 治疗计划可以包括分割患者的图像以界定接受治疗的区域，定义试验参数，根据试验参数模拟对患者的消融治疗的治疗; 分析由模拟治疗产生的热剂量分布，以确定治疗有效性; 确定治疗有效性何时达到治疗有效性标准; 并且当治疗效果满足治疗有效性标准时提供试验参数的指示。

公开(公告)号：US10607738B2

公开(公告)日：2020-03-31

申请号：US15154307

申请日：2016-05-13

Applicant: University Health Network ,  Sunnybrook Research Institute

Inventor： Sean Davidson ,  Michael D. Sherar ,  Kieran Murphy ,  Claire McCann ,  Robert Weersink

IPC: A61B34/32 ,  G16H50/50 ,  A61B34/00 ,  A61B34/10 ,  A61B18/00

Abstract: Various embodiments are described herein for a system and a method for treatment planning for providing ablative therapy to a patient. The treatment planning may involve segmenting images of the patient to define areas to receive treatment, defining trial parameters, simulating treatment of ablative therapy to the patient according to the trial parameters; analyzing a thermal dose distribution resulting from the simulated treatment to determine treatment effectiveness; determining when the treatment effectiveness meets a treatment effectiveness criteria; and providing an indication of the trial parameters when the treatment effectiveness meets the treatment effectiveness criteria.